Thyroid autoimmunity in patients with malignant and benign breast diseases before surgery

E Giustarini, A Pinchera, P Fierabracci, M Roncella, L Fustaino, C Mammoli and C Giani

Department of Endocrinology and Metabolism, University of Pisa, Pisa, Italy, and Department of Surgery, Unit of Senology, S.Chiara’s Hospital, Pisa, Italy

(Correspondence should be addressed to E Giustarini; Email: eligiustarini@hotmail.com)

Abstract

Background: Previous studies have demonstrated a high prevalence of thyroperoxidase antibodies (TPOAb) and autoimmune hypothyroidism in breast cancer (BC). These studies have been performed in BC patients generally 20–30 days after mastectomy. It is known that stress may have an influence on the immune system and a relation between stressful events and the onset or worsening of autoimmune thyroid disorders has been reported by several authors. The aim of the study was to evaluate the prevalence of autoimmune thyroid disease in patients with nodular breast disease selected for surgery before any treatment. Our hypothesis was that the high prevalence of thyroid autoimmune disorders in BC is independent of stressful events represented by surgery and/or anaesthetic procedures.

Methods: Our series included 61 consecutive women aged 52.8 ± 10.2 yrs (mean age ± s.d.) with nodular breast disease selected for breast surgery: 36 out of 61 of them (59%) had BC and 25 out of 61 had benign breast disease (BBD). Controls included 100 healthy age-matched women. All patients and control subjects were submitted to clinical, ultrasound thyroid evaluation and serum-free thyroxine (FT4), serum-free tri-iodothyronine (FT3), TSH, TPOAb and thyroglobulin antibodies (TgAb) determination.

Results: Mean FT3, FT4 and TSH concentration showed no differences between BC patients, BBD patients and controls. The prevalence of TPOAb in BC patients (12/36: 33.33%) was significantly higher than in BBD patients (5/25: 20%) (P < 0.01) and in controls (8/100: 8%) (P < 0.01). Similarly, the prevalence of TgAb in BC patients was 12 out of 36 (33.33%) significantly higher than that detected in BBD patients (4/25: 16%) (P < 0.01) and in controls (12/100: 12%) (P < 0.01). Of the 36 BC patients, 20 showed a diffuse hypoechoogenicity of the thyroid gland to ultrasound evaluation, significantly higher than in BBD (7/25: 28%) (P = 0.03). Of the 20 BC patients who showed a hypoechochogenic pattern of thyroid gland, 10 (50%) were associated with antithyroid antibodies positivity (TAb). This finding was present in two of seven BBD (28.57%) (P < 0.0001). Only two controls showed focal hypoechochogenicity of the thyroid gland. Generally, 24 out of 36 (66.7%) of BC and 9 out of 25 (36%) of BBD (P = 0.02) had signs of thyroid autoimmunity consistent with the hypoechochogenic pattern of thyroid gland associated or not with TAb; 2 out of 36 (5.55%) of BC and 1 out of 25 (4%) of BBD patients had autoimmune hypothyroidism and no hypothyroidism was found in controls.

Conclusions: The results of this study confirm the strong relation between thyroid autoimmunity and BC. This finding is independent of stressful events represented by surgery or anaesthetic procedures. The present data call attention to the usefulness of screening for autoimmune thyroid disorders in patients with nodular breast disease selected for surgery.
between stressful events and autoimmune hypothyroidism and the results are inconclusive. In addition, the relevance of stress events on the appearance of serum thyroid antibodies or on the variation of their serum concentration is still unknown. The aim of the present prospective study was to evaluate the prevalence of autoimmune thyroid disorders in a group of patients with breast diseases selected for surgery, before any treatment including surgery. This was to confirm the high prevalence of autoimmune thyroid disorders in BC patients and to demonstrate that this finding is independent of stressful events represented by surgical treatment and/or anaesthetic procedures.

Subjects and methods

Our series included 61 consecutive women aged 52.8 ± 10.2 yrs (mean age ± s.d.), with nodular breast pathology suspected for malignancy, referred to the Surgical Department of Pisa’s Hospital from May 2004 to March 2005 for breast surgery. After informed consent, all the patients were evaluated at the Department of Endocrinology and Metabolism of the same hospital for autoimmune thyroid disorder screening before surgical treatment. The mean latency period between the detection of breast lump and the first visit to the Surgical Department was 7 days and the patient was evaluated for thyroid autoimmunity the day after the first visit. The control group consisted of 100 healthy age-matched women living in the same borderline iodine sufficient geographic area. The body size of the patient group and the control group calculated as the body mass index (weight/(height)^2) was similar: 20 and 19 respectively. A family history of autoimmune thyroid disorder was found in 5 out of 61 (8.2%) patients with nodular breast diseases and in 4 out of 100 (4.0%) control subjects. All patients and controls were subjected to clinical and ultrasonographic thyroid evaluation and venous blood samples were drawn for free thyroxine (FT4), free tri-iodothyroxine (FT3), thyrotrophin (TSH), thyroglobulin antibodies (TgAb) and TPOAb determination. FT3 and FT4 were measured by RIA, using Liso-phase Kits from TecnoGenetics (Milan, Italy). The sensitivity was 0.5 pg/ml for FT3 and 0.8 pg/ml for FT4. TSH was measured by a solid phase, two-site, fluoroimmunometric assay using a commercially available Kit (Delfia hTSH, Pharmacia, Friburgo, Germany): detection limit was 0.03 mcU/ml. Normal ranges, defined as the mean ± 2s.d. values for healthy controls, were 2.7–5.7 pg/ml for FT3, 7–17 pg/ml for FT4, and 0.4–3.4 mcU/ml for TSH. TgAb and TPOAb were determined by two-step immunoenzymometric assay (ALPHA-PACK, Tosho Bioscience Inc., San Francisco, CA, USA). Briefly, TgAb or TPOAb present in the samples were bound to Tg or TPO antigens immobilized on the assay beads respectively. The beads were washed to remove unbound materials and then incubated with enzyme-labelled monoclonal anti-human IgG antibodies. The beads were washed again and then incubated with fluorogenic substrate. The amount of enzyme-labelled antibody bound to the beads is directly proportional to the TgAb or TPOAb in the samples. A standard curve using a range of known standard concentration was determined to measure unknown serum TgAb or TPOAb concentrations. Minimal detectable concentration of TgAb was 0.12 U/ml and of TPOAb was 0.05 U/ml; these values correspond to 12 and 8 U/ml in original serum samples diluted 1:50 in a sample diluting solution. Values of TgAb > 30 U/ml and TPOAb > 10 U/ml were considered positive for thyroid antibodies (TAb). Ultrasoundographic evaluation of thyroid gland was performed using a commercially available real-time instrument (Aloka SSD121, Aloka Co., Tokyo, Japan) using a 7.5 MHz linear transducer. Thyroid volume was calculated according to the method of Aghini-Lombardi et al. (18) and the level of echogenicity was evaluated according to the method of Marcocci et al. (19). The diagnosis of autoimmune thyroid disease was carried out according to clinical, hormonal and instrumental parameters; in particular, the presence of serum TAb and/or diffuse thyroid hypoechogenicity associated or not with goitre was indicative of autoimmune thyroiditis.

Statistical analysis

Statistical analysis was performed using Fisher’s exact test. A P value of <0.05 was considered significant.

Results

Thirty-six of sixty-one (59%) patients submitted to breast surgery for suspected nodular disease had BC, and 25 out of 61 (41%) had BBD. In the BC group the mean ± s.d. of serum FT4 and serum FT3 concentration was 9.76 ± 2.73 and 3.58 ± 0.7 pg/ml respectively, similar to those detected in both the BBD and control groups (FT4: 9.93 ± 2.12 and 9.9 ± 2.4 pg/ml, FT3: 3.65 ± 0.45 and 3.2 ± 0.6 pg/ml) respectively. The mean TSH concentration in BC was 1.9 ± 0.7 mcU/ml similar to those detected in both the BBD group and the control group (1.19 ± 0.85 and 1.8 ± 1.4 mcU/ml respectively).

The prevalence of TPOAb in the BC group was 12 out of 36 (33.33%) significantly higher than that detected in BBD patients (5/25: 20%) (P < 0.01), and in controls (8/100: 8%) (P < 0.01). The prevalence of TgAb in the BC group was 12/36 (33.33%), in BBD patients it was 4 out of 25 (16%) (P < 0.01), and in the control group it was 12% (P < 0.01) (Fig. 1). In the positive TPOAb group, a very high concentration of serum TPOAb was detected in 5 out of 12 (41.66%) BC patients and two of them showed values > 1000 U/ml in BBD 2 out of 5
patients (40.0%) had serum TPOAb values > 300 U/ml and only one > 1000 U/ml. In the positive TgAb group, a very high concentration of serum TgAb (>300 U/ml) was found in 8 out of 12 BC patients (66.66%) and in 1 out of 4 (25.0%) BBD patients. A diffuse hypoechogenicity of thyroid gland to ultrasound evaluation was found in 20 of 36 BC patients (55.55%) and in 7 out of 25 BBD patients (28%) ($P<0.03$) (Fig. 2). The hypoechogenic pattern of thyroid gland was associated with TAb positivity in 10 BC patients (10/20: 50%) and in 2 BBD patients (2/7: 28.57%) ($P<0.0001$) (Fig. 3). Sixteen BC patients showed a normal echographic pattern of thyroid gland and four of these (4/16: 25%) had positivity of circulant TAb, and in BBD patients 18 out of 25 (72%) had normal echographic thyroid pattern with the presence of circulant antithyroid antibodies in two (2/18: 11.11%). In the control group, a focal hypoechogenicity of the thyroid gland was found in only two subjects both with TPOAb positivity. In BC, 24 out of 36 (66.7%) had signs of thyroid autoimmunity consistent with the hypoechogenic pattern of the thyroid gland associated or not with the presence of antithyroid antibodies and in the BBD group was 9 out of 25 (36.0%). The difference was significant ($P=0.02$) (Fig. 4). No hyperthyroidism was found in patients with breast pathology or in the control group. Two BC patients (2/36: 5.55%) and 1 BBD patient (1/25: 4%) had autoimmune hypothyroidism. No hypothyroidism was found in the control group.

**Discussion**

Various authors have focused attention on the relationship between BC and thyroid disorders (1–3). In particular, a strong relationship between breast malignancy and thyroid autoimmune disorders has been
found by Giani et al. (1) and confirmed by Smyth et al. (2). All these studies have been carried out in BC patients after mastectomy and before beginning any chemo-hormonal adjuvant therapy. The impact of stressful events on immune response and, in particular, on the onset or precipitation of autoimmune thyroid disorders is controversial. In fact, an association between stressful life events and the onset of Graves’ disease has been observed in some (10–12) but not all studies (8, 13, 14). Most of these studies were retrospective, and the use of different diagnostic criteria for thyroid diseases, the difficult definition and quantification of stressful life events and the different criteria for control groups may account for these discrepancies.

Chiovato et al. (13, 14), in prospective studies with well-defined criteria for thyroid autoimmune disorders in a group of patients with panic disorders and agoraphobia, showed no association between chronic recurrent stress and Graves’ disease. Few studies are available on the relation between stress events and Hashimoto’s thyroiditis. Two retrospective studies reported no association between lymphocytic chronic thyroiditis and stress (16, 17). Probably the onset and course of Hashimoto’s thyroiditis are generally insidious and the patient does not become symptomatic until the development of hypothyroidism or goitre. This makes it difficult to evaluate the role of stress in the onset and/or course of these diseases. No data are available on the behaviour of thyroid antibodies after stress events.

In our study we confirmed the high prevalence of autoimmune thyroid diseases in BC. The prevalence of TgAb and/or TPOAb detected in the group of BC patients evaluated before surgery is similar to that found in a previous study in a group of BC patients examined after mastectomy (1). In addition, we detected a high prevalence of TgAb and/or TPOAb in a group of patients with BBD before surgery, significantly higher than that detected in the normal group and generally found in the normal population (20). Interestingly, a very high number of patients with BC had a diffuse hypoechogenicity of the thyroid gland and only half of them had antithyroid antibodies positivity. Since diffuse hypoechogenicity is a hallmark of thyroid autoimmunity, and the echographic pattern is indicative of diffuse autoimmune involvement of the thyroid gland (19) we cannot exclude the possibility that this group of BC patients might have autoimmune thyroiditis and develop autoimmune hypothyroidism.

In general, signs of thyroid autoimmunity, including diffuse hypoechogenicity of the thyroid gland associated or not with the presence of circulating antithyroid antibodies, were detected in the majority of BC patients at significantly higher levels than those detected in BBD patients. The results of this study confirm a strong relationship between thyroid autoimmunity and BC. For the first time we have demonstrated that this relationship is also present before surgery and any anti-tumoural treatment. In addition, we have demonstrated a high incidence of thyroid autoimmune disorders in BBD, but at less significant values with respect to breast malignancies. In conclusion, we confirm that all patients with breast pathology should be evaluated for thyroid autoimmune disorders, possibly to detect BC patients with hypothyroidism who need substitutive treatment before surgical treatment.

References


---

Received 16 November 2005
Accepted 9 December 2005